News from allergan A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

27 Jul, 2017, 00:30 BST Allergan's Truberzi® (eluxadoline) Receives Positive Recommendation from NICE for the Treatment of Irritable Bowel Syndrome with Diarrhoea (IBS-D) in Adults

Allergan announced today that the National Institute of Health and Care Excellence (NICE) has published a Final Appraisal Determination, recommending ...


01 Jul, 2016, 09:42 BST New Global Research from Allergan Shows New Attitude to Beauty as Women Seek Confidence Over Youth

-- First and largest of its kind research captures the attitudes of nearly 8,000 women across 16 countries and identifies a new age of beauty...


04 Nov, 2015, 10:00 GMT Allergan to Acquire earFold™, an Innovative Medical Device for the Correction of Prominent Ears

Complements Allergan's leadership position in Medical Aesthetics and enhances offering to Plastic Surgeons earFold™, for the correction of prominent...


16 Dec, 2014, 07:30 GMT New Research from Allergan Reveals that the Quest to Look Younger is No Longer a Beauty Priority for Women

New research conducted by Allergan, the maker of JUVÉDERM® facial fillers, has revealed that even when surrounded by images of smooth...


01 May, 2014, 10:32 BST BOTOX® (Botulinum Toxin Type A) Receives a Positive Opinion in Fourteen European Countries for the Treatment of Focal Spasticity of the Ankle in Adult Post Stroke Patients

This Positive Opinion Paves the Way for a Second Indication for BOTOX® in Adult Spasticity Associated with Stroke Today, Allergan Inc. announced that ...


04 Feb, 2014, 14:25 GMT BOTOX® (Botulinum toxin type A) Receives Approval in the UK for the Treatment of Ankle Disability due to Lower Limb Spasticity Associated with Stroke in Adults

BOTOX® becomes the first and only neuromodulator to be approved specifically for the treatment of both upper and lower limb spasticity in adults who...


09 Jan, 2014, 00:01 GMT Allergan's BOTOX® (botulinum toxin type A) Receives National Marketing Authorisation for Treatment of Moderate to Severe Crow's Feet Lines in Adult Patients

 New aesthetic indication for market-leading neuromodulator which can now help improve appearance of lines around the eyes, as well as treating...


23 Oct, 2013, 00:01 BST Allergan's VISTABEL® (Botulinum Toxin Type A) Receives Europe's First Positive Opinion for Treatment of Moderate to Severe Lateral Canthal Lines (Crow's Feet Lines) in Adult Patients

Positive Opinion Paves the Way for a Second Aesthetic Indication for VISTABEL® in 29 European Countries Today, Allergan Inc. announced that VISTABEL® ...


11 Sep, 2013, 00:01 BST Allergan's BOTOX® (botulinum toxin type A) Receives Authorisation for the Treatment of Overactive Bladder in the UK

BOTOX® injections provide a new and long lasting approach to the management of overactive bladder Today, Allergan Inc. announced that BOTOX® has been ...


09 Jul, 2013, 00:01 BST JUVEDÉRM® VOLBELLA® with Lidocaine: A New Dermal Filler For Lips, Uniquely Designed for a Natural Look

Allergan today announced the launch of JUVÉDERM® VOLBELLA® with Lidocaine, a new dermal filler treatment specifically tailored for the lips and the...


19 Dec, 2012, 05:00 GMT Allergan's BOTOX® (botulinum toxin type A) Receives a Positive Opinion in Fourteen European Countries for Idiopathic Overactive Bladder

Data demonstrates BOTOX® injections can reduce urinary leakage episodes for up to six months in patients who have had an inadequate response to, or...


27 Sep, 2012, 08:30 BST Allergan's BOTOX® (Botulinum Toxin Type A) Receives UK Authorisation for Urinary Leakage in Patients With Multiple Sclerosis or Spinal Cord Injury

Allergan, Inc. is pleased to announce that BOTOX® has been licensed by the Medicines and Healthcare Products Regulatory Agency (MHRA) for the...


27 Jun, 2012, 07:00 BST BOTOX® (Allergan's botulinum toxin type A) Given Final Guidance from the National Institute for Health and Clinical Excellence (NICE) for the Prevention of Chronic Migraine in Patients Who Have Failed Previous Treatments

Allergan announced today that the National Institute for Health and Clinical Excellence (NICE) has issued its Final Guidance giving the green light...


11 May, 2012, 00:01 BST BOTOX® (Allergan's Botulinum Toxin Type A) Recommended by the National Institute for Health and Clinical Excellence (NICE) for the Prevention of Chronic Migraine in Patients Who Have Failed Previous Treatments

Allergan announced today that the National Institute for Health and Clinical Excellence (NICE) is recommending BOTOX® (botulinum toxin type A) for...


08 May, 2012, 09:00 BST Allergan Launches First EU Public Awareness & Education Campaign on the Importance of Quality in Medical Aesthetics

Allergan today announces the European launch of their landmark public awareness and education initiative highlighting the importance of quality in...


27 Jul, 2011, 16:28 BST NICE Recommends OZURDEX(R), an Innovative Treatment for Retinal Vein Occlusion (RVO), a Common Cause of Vision Loss

Allergan announces today that the National Institute for Health and Clinical Excellence (NICE) has issued final guidance recommending OZURDEX®...


08 Jun, 2011, 11:21 BST First Head-to-head Study in Branch Retinal Vein Occlusion(BRVO) Announced in Europe and Israel

- First Patient to be Enrolled in Comparison of Intravitreal Dexamethasone Implant and Ranibizumab for Macular Oedema in BRVO (COMO) Study This...


06 Jun, 2011, 00:01 BST NICE Recommends OZURDEX(R), an Innovative Treatment for Retinal Vein Occulsion (RVO), a Common Cause of Vision Loss

Allergan announces today that the National Institute for Health and Clinical Excellence (NICE) has recommended OZURDEX(R) (dexamethasone 0.7mg...